{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:07:36Z","timestamp":1789204056475,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijmmb.2026.101185","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:31:06Z","timestamp":1782257466000},"page":"101185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Susceptibility-guided versus empirical therapy for Helicobacter pylori infection: a meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"63","author":[{"given":"Tingru","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2026.101185_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101185_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2025.08.015","article-title":"The disease burden of Helicobacter pylori beyond gastric cancer: quantifying the forgotten potential benefits of mass eradication","volume":"170","author":"M\u00fclder","year":"2026","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101185_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl20288","article-title":"Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020","volume":"15","author":"Jung","year":"2021","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.ijmmb.2026.101185_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.5009\/gnl240489","article-title":"Korean Registry on the current management of Helicobacter pylori (K-Hp-Reg): interim analysis of adherence to the revised evidence-based guidelines for first-line treatment","volume":"19","author":"Yang","year":"2025","journal-title":"Gut Liver"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101185_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/gut.2009.192757","article-title":"Helicobacter pylori treatment in the era of increasing antibiotic resistance","volume":"59","author":"Graham","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ijmmb.2026.101185_bib6","article-title":"Helicobacter pylori antibiotic resistance in Russia: a systematic review and meta-analysis","volume":"14","author":"Andreev","year":"2025","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101185_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/hel.13076","article-title":"14-day tailored PCR-guided triple therapy versus 14-day non-bismuth concomitant quadruple therapy for Helicobacter pylori eradication: a multicenter, open-label randomized noninferiority controlled trial","volume":"29","author":"Amiot","year":"2024","journal-title":"Helicobacter"},{"issue":"10","key":"10.1016\/j.ijmmb.2026.101185_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1038\/ajg.2014.222","article-title":"Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance","volume":"109","author":"Park","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.ijmmb.2026.101185_bib9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/apt.15273","article-title":"Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment","volume":"49","author":"Chen","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ijmmb.2026.101185_bib10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.medmal.2019.06.001","article-title":"Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection","volume":"50","author":"Delchier","year":"2020","journal-title":"Med Mal Infect"},{"issue":"7","key":"10.1016\/j.ijmmb.2026.101185_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/ueg2.12609","article-title":"Culture-based susceptibility-guided tailored versus empirical concomitant therapy as first-line Helicobacter pylori treatment: a randomized clinical trial","volume":"12","author":"Lee","year":"2024","journal-title":"United Eur Gastroenterol J"},{"issue":"9","key":"10.1016\/j.ijmmb.2026.101185_bib12","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/00365521.2021.1948606","article-title":"Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area","volume":"56","author":"Cha","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101185_bib19","first-page":"597","article-title":"Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate","volume":"113","author":"Bonoso","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"issue":"10","key":"10.1016\/j.ijmmb.2026.101185_bib20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/1751-2980.12934","article-title":"Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: a randomized controlled trial","volume":"21","author":"Ji","year":"2020","journal-title":"J Dig Dis"},{"issue":"3","key":"10.1016\/j.ijmmb.2026.101185_bib21","first-page":"163","article-title":"The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication","volume":"3","author":"Avidan","year":"2001","journal-title":"Isr Med Assoc J"},{"issue":"6","key":"10.1016\/j.ijmmb.2026.101185_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/14787210.2022.2017280","article-title":"Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial","volume":"20","author":"Cho","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101185_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus triple plus bismuth or concomitant therapy as initial Helicobacter pylori treatment: a randomized trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"issue":"5","key":"10.1016\/j.ijmmb.2026.101185_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/hel.12654","article-title":"Helicobacter pylori eradication rates with concomitant and tailored therapy based on 23S rRNA point mutation: a multicenter randomized controlled trial","volume":"24","author":"Ong","year":"2019","journal-title":"Helicobacter"},{"issue":"1","key":"10.1016\/j.ijmmb.2026.101185_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/hel.70018","article-title":"Is tailored bismuth quadruple therapies (with clarithromycin or furazolidone) based on fecal molecular susceptibility testing in first-line Helicobacter pylori eradication treatment more effective? A three-arm, multicenter randomized clinical trial","volume":"30","author":"Yu","year":"2025","journal-title":"Helicobacter"},{"issue":"6","key":"10.1016\/j.ijmmb.2026.101185_bib26","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/MPG.0b013e318229c769","article-title":"Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children","volume":"53","author":"Bontems","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"10.1016\/j.ijmmb.2026.101185_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1046\/j.1365-2036.2003.01541.x","article-title":"Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?","volume":"17","author":"Miwa","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101185_bib28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2036.2003.01757.x","article-title":"Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments","volume":"18","author":"Neri","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.ijmmb.2026.101185_bib29","first-page":"S171","article-title":"Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities","volume":"23","author":"Kawai","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101185_bib30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-5378.2006.00407.x","article-title":"Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole","volume":"11","author":"Marzio","year":"2006","journal-title":"Helicobacter"},{"issue":"11","key":"10.1016\/j.ijmmb.2026.101185_bib31","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1111\/j.1572-0241.2000.03317.x","article-title":"Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection","volume":"95","author":"Romano","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101185_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2018.06.047","article-title":"Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection","volume":"155","author":"Liou","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ijmmb.2026.101185_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060534","article-title":"Randomized clinical trial comparing concomitant and tailored therapy for eradication of Helicobacter pylori infection","volume":"11","author":"Perkovic","year":"2021","journal-title":"J Pers Med"},{"issue":"47","key":"10.1016\/j.ijmmb.2026.101185_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002056","article-title":"Multiple genetic analysis system-based antibiotic susceptibility testing in Helicobacter pylori and high eradication rate with phenotypic resistance-guided quadruple therapy","volume":"94","author":"Dong","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"12","key":"10.1016\/j.ijmmb.2026.101185_bib35","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/MEG.0000000000000197","article-title":"Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions","volume":"26","author":"Martos","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101185_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","article-title":"Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori","volume":"81","author":"Furuta","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ijmmb.2026.101185_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1542-3565(03)00131-9","article-title":"Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori","volume":"1","author":"Romano","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.ijmmb.2026.101185_bib38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1046\/j.1365-2036.2000.00870.x","article-title":"Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication","volume":"14","author":"Toracchio","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ijmmb.2026.101185_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11684-019-0706-8","article-title":"Is tailored therapy based on antibiotic susceptibility effective? A multicenter, open-label, randomized trial","volume":"14","author":"Pan","year":"2020","journal-title":"Front Med"},{"issue":"8","key":"10.1016\/j.ijmmb.2026.101185_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2036.2003.01759.x","article-title":"Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies","volume":"18","author":"Lamouliatte","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"31","key":"10.1016\/j.ijmmb.2026.101185_bib41","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.3748\/wjg.v27.i31.5247","article-title":"Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients","volume":"27","author":"Choi","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"10","key":"10.1016\/j.ijmmb.2026.101185_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15100458","article-title":"Tailored therapy vs. empirical therapy for Helicobacter pylori eradication: an umbrella review of systematic reviews and meta-analyses","volume":"15","author":"Andreev","year":"2025","journal-title":"J Pers Med"},{"issue":"10 Suppl 2","key":"10.1016\/j.ijmmb.2026.101185_bib14","article-title":"S2119 tailored culture\/PCR-guided therapy beats concomitant quadruple for H. pylori with 9% cure rate and 33% fewer adverse events: an updated systematic review and meta-analysis of randomized controlled trials","volume":"120","author":"Das","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"10 Suppl 2","key":"10.1016\/j.ijmmb.2026.101185_bib15","article-title":"S2097 comparative efficacy of tailored and concomitant therapy as first-line treatment for H. pylori: a systematic review and meta-analysis","volume":"120","author":"Chaudhary","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijmmb.2026.101185_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231196357","article-title":"Empirical versus tailored therapy based on genotypic resistance detection for Helicobacter pylori eradication: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2023","journal-title":"Therapeut Adv Gastroenterol"},{"issue":"2","key":"10.1016\/j.ijmmb.2026.101185_bib17","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000792","article-title":"Accuracy of fecal polymerase chain reaction testing in clarithromycin-resistant helicobacter pylori: a systematic review and meta-analysis","volume":"16","author":"Al Qady","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ijmmb.2026.101185_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1592612","article-title":"Clinical evaluation of a novel H. pylori fecal molecular diagnosis kit (multiplex RT-PCR method) for detecting clarithromycin and fluoroquinolones resistance using stool samples","volume":"15","author":"Wei","year":"2025","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572600143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572600143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:20:41Z","timestamp":1789201241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S025508572600143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"alternative-id":["S025508572600143X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101185","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility-guided versus empirical therapy for Helicobacter pylori infection: a meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2026.101185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Indian Association of Medical Microbiologists.","name":"copyright","label":"Copyright"}],"article-number":"101185"}}